Massed Prolonged Exposure for PTSD in Substance Use Treatment

Substance Use Disorders Clinical Trial

— PREVAIL  

Official title:

Clinical Effectiveness and Implementation of Massed Prolonged Exposure for PTSD Among Veterans in Intensive Outpatient Substance Use Treatment (MPE)

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06296186
• Other study ID #: HT94252310669
• Status: Not yet recruiting
• Phase: N/A
• Start date: May 2024
• Est. completion date: August 2027

Study information

• Verified date: February 2024
• Source: Veterans Medical Research Foundation
• Contact: Sonya Norman, PhD
• Phone: 858-518-8266
• Email: snorman[@]ucsd.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this clinical trial is to learn if receiving Prolonged Exposure Therapy for PTSD in massed format (multiple sessions weekly) is as effective as receiving it with sessions once per week among veterans with PTSD and substance use disorder in intensive outpatient substance use treatment. The main questions it aims to answer are:

• Will the massed format help participants complete and benefit from Prolonged Exposure in terms of PTSD symptoms?

• Will it help participants reduce substance use? Participants who are in intensive substance use treatment will be asked to complete Prolonged Exposure with either weekly sessions or multiple sessions per week.

Description:

Posttraumatic stress disorder (PTSD) and substance use disorder (SUD) often co-occur. PTSD+SUD comorbidity is associated with more severe PTSD, worse treatment outcomes for substance use, greater suicide risk and worse functioning than having one of these disorders. First-line treatments for PTSD, particularly Prolonged Exposure Therapy (PE), are effective in treating PTSD among those with a SUD, and delivering these treatments concurrent to SUD programming is recommended by the VA/DoD Clinical Practice Guidelines. While PE is one of the most effective treatment options for PTSD among those with PTSD+SUD, effects are smaller and dropout is higher than among people with PTSD without a SUD. A promising way to enhance outcomes is to offer PE in a massed format (M-PE; i.e., multiple sessions per week instead of once weekly). M-PE has been shown to be effective in improving PTSD symptoms and substantially reducing dropout in military and Veteran populations. Preliminary findings suggest M-PE delivered concurrent to intensive SUD programming is a promising strategy that warrants further study. Evaluating the effectiveness of M- PE delivery in of SUD intensive outpatient programming (IOP) in improving PTSD and other mental health outcomes and reducing dropout as compared to weekly PE delivery (W-PE) is the necessary next step in this critical research.

The primary goal of this project is to determine if a promising way to treat PTSD among those with SUD, M-PE, will help Veterans with their PTSD symptoms and lead to better treatment completion rates more than PE delivered weekly and if the massed format will reduce substance use comparably to weekly PE among those in intensive SUD treatment. The study will also evaluate if M-PE helps Veterans function better and feel less depressed. M-PE is a one-on-one talk therapy that is delivered over twelve sessions several times a week. The therapy is brief because of the massed format so that it can be delivered at times when lengthy interventions may not be realistic, such as military mental health clinics on bases where military personnel may be getting ready to redeploy. The research team's preliminary work with Veterans in intensive SUD treatment showed M-PE to lead to improvements in PTSD and depression symptoms with no dropout, making this larger evaluation of M-PE compared to PE delivered in the traditional longer (weekly) format a critical next step. The study will accomplish this by randomly assigning participants who are in intensive SUD treatment to receive either M-PE or W-PE. The study will have 200 Veterans who served post 9/11 go through this study and the entire study is expected to take four years to complete. The study will run the study across four VAs (San Diego, Tampa, Chicago, and Atlanta).

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 200
• Est. completion date: August 2027
• Est. primary completion date: July 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Veterans

• age 18+

• who have served since September 2001

• who are enrolled in a SUD IOP at a participating VA

• meet DSM-5 criteria for a current SUD (Tobacco Use Disorder alone not sufficient for inclusion)

• meet DSM-5 criteria for PTSD

• report substance use at least 20 of the last 90 days

• are able to give informed consent.

Exclusion Criteria:

• severe cognitive impairment

• current suicidal or homicidal intent requiring immediate treatment

• current unstable psychotic or manic symptoms not attributable to SUD

Related Conditions & MeSH terms

• Stress Disorders, Post-Traumatic
• Substance Use Disorders
• Substance-Related Disorders

Intervention

Behavioral:
• Prolonged Exposure Therapy
Exposure therapy for PTSD

Locations

Country	Name	City	State
United States	VA Atlanta Healthcare System	Atlanta	Georgia
United States	Hines VA Healthcare System	Chicago	Illinois
United States	VA San Diego Healthcare System	San Diego	California
United States	VA Tampa Healthcare System	Tampa	Florida

Sponsors (3)

Lead Sponsor	Collaborator
Veterans Medical Research Foundation	Center for Veterans Research and Education, University of Minnesota

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Clinician Administered PTSD Scale for DSM-5 (CAPS-5)	Measures PTSD symptom severity, score range 0-80, higher scores mean greater symptom severity	At 4-, 16-, 28-, and 40-weeks post-first therapy session
Primary	Time Line Follow back (TLFB)	Measures percent days of alcohol or other drug use, score range 0-100%, higher scores indicate greater percent days of use	At 4-, 16-, 28-, and 40-weeks post-first therapy session
Primary	Psychotherapy Completion Rates	Percent of participants completing all sessions of psychotherapy, range is 0-100%, higher number means greater percent completed therapy	16 weeks
Secondary	Patient Health Questionnaire-9 (PHQ-9)	Depression symptom severity, range = 0-27, higher scores mean greater depression symptom severity	At 4-, 16-, 28-, and 40-weeks post-first therapy session
Secondary	Brief Psychosocial Functioning Inventory (B-IPF)	Measures severity of impairment in psychosocial functioning, scores = 0-100, higher scores indicate greater impairment	At 4-, 16-, 28-, and 40-weeks post-first therapy session
Secondary	Client Satisfaction Questionnaire-8 (CSQ-8)	Measures satisfaction with treatment, scores range from 8 to 32. higher scores indicate greater satisfaction with treatment	16 weeks